COMMUNIQUÉS West-GlobeNewswire

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
07/05/2025
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 07 mai 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]
Monthly information on share capital and company voting rights
07/05/2025
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, May 07, 2025 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the capital [...]
Nyxoah to Release First Quarter 2025 Financial Results on May 14, 2025
07/05/2025
Nyxoah to Release First Quarter 2025 Financial Results on May 14, 2025 Mont-Saint-Guibert, Belgium – Wednesday May 7, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company [...]
Nyxoah Publiera ses Résultats Financiers du Premier Trimestre 2025 le 14 Mai 2025
07/05/2025
Nyxoah Publiera ses Résultats Financiers du Premier Trimestre 2025 le 14 Mai 2025 Mont-Saint-Guibert, Belgique – 7 mai 2025, 22h30 CET / 16h30 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société [...]
Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology
07/05/2025
Study suggests that utilizing RiskScore drives breast cancer screening tailored to individual risk SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostic [...]
STERIS Declares Dividend of $0.57 per share
07/05/2025
DUBLIN, IRELAND, May 07, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. The dividend is [...]
DLH Reports Fiscal 2025 Second Quarter Results
07/05/2025
Solid Cash Flow and Debt Reduction Strengthen Financial Outlook as Bid Activity Accelerates ATLANTA, May 07, 2025 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of [...]
Korro Reports First Quarter 2025 Financial Results and Provides Business Updates
07/05/2025
— Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD) on track for the second half of 2025 — Streamlining operations and focusing on delivering potential value [...]
Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update
07/05/2025
Catalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook Delivers Record Q1 2025 Total Revenues of $141.4 Million, a 43.6% YoY Increase FIRDAPSE® and AGAMREE® Drive Sustained Organic Growth [...]
Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy
07/05/2025
MELBOURNE, Australia and INDIANAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its Fibroblast Activation Protein (FAP)-targeting [...]
Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update
07/05/2025
- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update at 2025 ASCO ® Annual Meeting - Based on the Company’s current operating plan, existing cash, cash [...]
GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory Documents
07/05/2025
Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); May 7, 2025 - GENFIT (Nasdaq and Euronext: GNFT) , a biopharmaceutical company dedicated to improving the lives of patients with rare and [...]
GENFIT : Assemblée Générale Mixte du 17 juin 2025 — modalités de mise à disposition des documents préparatoires
07/05/2025
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 7 mai 2025 – GENFIT (Nasdaq et Euronext : GNFT) , société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de [...]
Oncocyte to Release First Quarter 2025 Results on May 12, 2025
07/05/2025
IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes [...]
Context Therapeutics Reports First Quarter 2025 Operating and Financial Results
07/05/2025
CTIM-76 and CT-95 in Phase 1 Clinical Trials Cash and cash equivalents of $89.4 million as of March 31, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, May 07 [...]
MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance
07/05/2025
ROCKVILLE, MD, May 7, 2025 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of [...]
ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update
07/05/2025
1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue ( 1 ) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA ( 2 ) of $47.9 Million, [...]
Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference
07/05/2025
SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked [...]
LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
07/05/2025
New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 Cash, cash equivalents and marketable securities of $194.1 million as of March 31, 2025 Upwardly [...]

Pages